These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 34316017)
1. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Rücker FG; Du L; Luck TJ; Benner A; Krzykalla J; Gathmann I; Voso MT; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Savoie L; Sierra J; Pallaud C; Sanz MA; Jansen JH; Niederwieser D; Fischer T; Ehninger G; Heuser M; Ganser A; Bullinger L; Larson RA; Bloomfield CD; Stone RM; Döhner H; Thiede C; Döhner K Leukemia; 2022 Jan; 36(1):90-99. PubMed ID: 34316017 [TBL] [Abstract][Full Text] [Related]
2. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241 [TBL] [Abstract][Full Text] [Related]
3. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Kayser S; Schlenk RF; Londono MC; Breitenbuecher F; Wittke K; Du J; Groner S; Späth D; Krauter J; Ganser A; Döhner H; Fischer T; Döhner K; Blood; 2009 Sep; 114(12):2386-92. PubMed ID: 19602710 [TBL] [Abstract][Full Text] [Related]
4. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Liu SB; Qiu QC; Bao XB; Ma X; Li HZ; Liu YJ; Chen SN; Song YH; Wu DP; Xue SL Cancer Sci; 2018 Dec; 109(12):3981-3992. PubMed ID: 30320942 [TBL] [Abstract][Full Text] [Related]
5. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Schlenk RF; Kayser S; Bullinger L; Kobbe G; Casper J; Ringhoffer M; Held G; Brossart P; Lübbert M; Salih HR; Kindler T; Horst HA; Wulf G; Nachbaur D; Götze K; Lamparter A; Paschka P; Gaidzik VI; Teleanu V; Späth D; Benner A; Krauter J; Ganser A; Döhner H; Döhner K; Blood; 2014 Nov; 124(23):3441-9. PubMed ID: 25270908 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446 [TBL] [Abstract][Full Text] [Related]
7. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053 [TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M; Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297 [TBL] [Abstract][Full Text] [Related]
10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
11. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546 [TBL] [Abstract][Full Text] [Related]
12. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660 [TBL] [Abstract][Full Text] [Related]
13. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype. Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001 [TBL] [Abstract][Full Text] [Related]
14. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related]
15. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276 [TBL] [Abstract][Full Text] [Related]
16. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052 [TBL] [Abstract][Full Text] [Related]
17. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323 [TBL] [Abstract][Full Text] [Related]
19. Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. Koszarska M; Meggyesi N; Bors A; Batai A; Csacsovszki O; Lehoczky E; Adam E; Kozma A; Lovas N; Sipos A; Krahling T; Dolgos J; Remenyi P; Fekete S; Masszi T; Tordai A; Andrikovics H Leuk Lymphoma; 2014 Jul; 55(7):1510-7. PubMed ID: 24090502 [TBL] [Abstract][Full Text] [Related]
20. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]